| Mrs Julia Alice Davis, LMFT | |
|
414 S Main St Ste 208c, Rochester, MI 48307-2070 | |
| (248) 764-5550 | |
| (248) 287-4123 |
| Full Name | Mrs Julia Alice Davis |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 414 S Main St Ste 208c, Rochester, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306181292 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 91207 (California) | Secondary |
| 106H00000X | Marriage & Family Therapist | 4101006762 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Julia Alice Davis, LMFT 414 S Main St Ste 208c, Rochester, MI 48307-2070 Ph: (248) 764-5550 | Mrs Julia Alice Davis, LMFT 414 S Main St Ste 208c, Rochester, MI 48307-2070 Ph: (248) 764-5550 |
News Archive
Following controversy surrounding a study published in the Lancet earlier this month that examined the impact of the Millennium Villages Project (MVP) on child mortality, "both the authors of the paper and the journal itself have finally responded," blogger Matt Collin writes in the Aid Thoughts blog and provides a link to the post in the World Bank's "Development Impact" blog that began the debate.
Using a zebrafish model of a human genetic disease called neurofibromatosis (NF1), a team from the Perelman School of Medicine at the University of Pennsylvania has found that the learning and memory components of the disorder are distinct features that will likely need different treatment approaches.
Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.
Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.
› Verified 5 days ago
Heidi Doran, LMFT, LLP, LLPC Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 71 Walnut Blvd Ste 109, Rochester, MI 48307 Phone: 231-794-1447 | |
Mrs. Robin Nicole Kim, MA MFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 71 Walnut Blvd Ste 109, Rochester, MI 48307 Phone: 248-657-7875 |